Pepticom has just secured some $6.6 million in a series A financing round to advance innovative therapies for autoimmune illnesses. The company, which develops artificial intelligence-driven peptide-based therapeutics, secured the funding from Japan-Israel High Tech Ventures 2 LP, with continued support from existing investors.